Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
16 December, 2017 08:55 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
BHEL wins order worth Rs 73 bn from TANGEDCO - 15-Dec-2017 15:05
Wipro's Topcoder launches 'Topcoder Veterans Community' - 15-Dec-2017 10:23
Yes Bank intends to acquire 5.62% stake in OPOSL - 14-Dec-2017 10:13
Hexaware Tech enters into partnership with Pegasystems - 14-Dec-2017 10:10
Bharti Airtel sells 20% stake in DTH arm to Warburg Pincus - 13-Dec-2017 11:24
Seamec enters into contract with Dolphin Offshore for 'SEAMEC III' - 13-Dec-2017 11:13
Asian Paints acquires 100% stake in Reno for Rs 1.59 bn - 13-Dec-2017 10:18
Punj Lloyd wins orders worth Rs 14.53 bn from GAIL, NHAI - 13-Dec-2017 10:14
JB Chemicals receives USFDA nod for Atenolol tablets - 13-Dec-2017 10:08
Kalpataru Power bags new orders worth Rs 8.75 bn - 13-Dec-2017 10:05
Ramco Systems wins order from SUEZ Middle East Water Services - 12-Dec-2017 15:22
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer